Trial reportThe quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of...2019
Copper-64 trastuzumab PET imaging: a reproducibility study.
Trial report in The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of..., 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review.Frontiers in medicine · 2022Pooled it
- Pharmacokinetics, Biodistribution, and Radiation Dosimetry forJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018Trial
- Precision theranostics in oncology: integrating antibody-drug conjugates, radioimmunotherapy, and immuno‑PET for adaptive cancer care.Discover oncology · 2026Review
- Radionuclide-based pharmaceuticals for breast cancer imaging: state of the art.EJNMMI radiopharmacy and chemistry · 2026Review
- Comprehensive advances in HER2-positive and HER2-negative breast cancer: unveiling molecular mechanisms and exploring cutting-edge targeted therapies for enhanced patient outcomes.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Development and clinical evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Radiolabeled HER2-targeted molecular probes in breast cancer imaging: current knowledge and future prospective.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Novel Molecular Classification of Breast Cancer with PET Imaging.Medicina (Kaunas, Lithuania) · 2024Review
- Molecular probes targeting HER2 PET/CT and their application in advanced breast cancer.Journal of cancer research and clinical oncology · 2024Review
- Advances and challenges in immunoPET methodology.Frontiers in nuclear medicine · 2024Review
- Review
- PET/CT and SPECT/CT Imaging of HER2-Positive Breast Cancer.Journal of clinical medicine · 2023Review
- From bench to bedside:EJNMMI research · 2023Article
- Synthesis and In Vitro Comparison of DOTA, NODAGA and 15-5 Macrocycles as Chelators for theMolecules (Basel, Switzerland) · 2022Article
- Imaging for illuminating actionable pathways in breast cancer.Current opinion in oncology · 2022Review
- Immuno-PET: Design options and clinical proof-of-concept.Frontiers in medicine · 2022Review
- Theranostic Advances in Breast Cancer in Nuclear Medicine.International journal of molecular sciences · 2021Review
- PET and SPECT Imaging of the EGFR Family (RTK Class I) in Oncology.International journal of molecular sciences · 2021Review
- Review
- ImmunoPET Imaging of Endogenous and Transfected Prolactin Receptor Tumor Xenografts.Molecular pharmaceutics · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundThe current study aims to assess the safety, pharmacokinetics, feasibility, and reproducibility of immunoPET imaging with copper-64 (64Cu) trastuzumab.
methodsAn IV injection of 296-370 MBq/5 mg 64Cu-trastuzumab was administered between 1 to 4 hours after routine trastuzumab treatment. Whole-body PET scans were performed immediately post-injection and at 24 hours post-injection. Serial pharmacokinetics were performed. Of 11 patients (median age of 52; range of 31-61), 8 underwent a repeat study with 64Cu-trastuzumab to assess image and pharmacokinetic reproducibility. Patients were monitored for toxicity.
resultsPatients experienced no allergic reactions or significant adverse effects from 64Cu-trastuzumab. Eight patients successfully completed a repeat 64Cu-trastuzumab study, with acceptable reproducibility of both the biodistribution and pharmacokinetic clearance. Study 1 versus study 2 showed similar serum concentration post-injection (mean 42.4±7.8 %ID/L vs. 44.7±12.6 %ID/L) and similar T1/2 (single exponential 46.1 vs. 44.2 hours), P>0.5. The volume of distribution (median 2.50 L) was in the range reported for trastuzumab and close to the estimated plasma volume of 2.60 L. Of 11 patients, two had 64Cu-trastuzumab localization corresponding to known tumor sites - one in liver and one in breast.
conclusionsPreliminary results suggest that scanning with 64Cu-trastuzumab is feasible, safe, and reproducible. Tumor uptake of 64Cu-trastuzumab was observed, but tumor detection exhibited low sensitivity in this study in which imaging was performed in the presence of trastuzumab therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.